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Abstract
Purpose The safety and efficacy of a minimally interrupted novel oral anticoagulant (NOAC) strategy at the time of atrial
fibrillation (AF) ablation is uncertain. The purpose of this study was to compare rates of bleeding and thromboembolic events
between minimally interrupted NOAC and uninterrupted vitamin K antagonist (VKA) in patients undergoing AF ablation.
Methods This was a retrospective single-center cohort study of consecutive patients who underwent AF catheter ablation
between January 2013 and April 2017. Endpoints included major bleeding, clinically relevant non-major bleeding and systemic
thromboembolic event from the time of ablation through 30 days. Bleeding events were defined by the Bleeding Academic
Research Consortium (BARC) and International Society on Thrombosis and Haemostasis (ISTH).
Results A total of 637 patients were included in the analysis, 520 patients used uninterrupted VKA and 117 patients minimally
interrupted NOAC (dabigatran: n = 68; apixaban: n = 30; rivaroxaban, n = 14; edoxaban, n = 5). The rate of clinically relevant
non-major bleeding was lower in the NOAC group in comparison to the VKA group (BARC type 2: 2.6% versus 8.3%, P = 0.03;
ISTH: 0% versus 3.8%, P = 0.03). Rates of major bleeding were similar between groups (BARC type 3 to 5: 3.4% versus 4.2%,
P = NS; ISTH: 6.0% versus 8.7%, P = NS; for NOAC and VKA groups, respectively). Rates of systemic embolismwere 0%with
minimally interrupted NOAC, and 0.6% with uninterrupted VKA (P =NS).
Conclusions In patients undergoing AF ablation, anticoagulation with minimally interrupted NOAC was associated with fewer
clinically relevant non-major bleeding events in comparison with uninterrupted VKAwithout compromising thromboembolic
safety.
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1 Introduction
Catheter ablation is increasingly used for the treatment of
symptomatic atrial fibrillation (AF). Although catheter abla-
tion of AF is considered safe, it may be associated with a low
risk of stroke. One of the strategies to reduce this risk is to
perform AF ablation with continuous oral anticoagulation.
This strategy has been shown to be safe and effective with
vitamin K antagonists (VKAs) [1]. However, there is an in-
creased use of novel oral anticoagulants (NOACs) in the cur-
rent AF population undergoing catheter ablation. NOACs
have several advantages, including a rapid onset of therapeutic
range of anticoagulation, predictability of the anticoagulant
effect, and relatively short time to reversal of anticoagulation
when the medication is withheld [2]. Several observational
and randomized controlled trials (RCTs) have demonstrated
that uninterrupted NOAC is as safe and effective in compari-
son to uninterrupted VKA in patients undergoing AF ablation
[3–13]. A recent meta-analysis demonstrated that NOAC was
even associated with less major bleeding compared with VKA
in pooled RCTs [14]. The 2016 ESC guidelines give a class IIa
indication to perform AF ablation with continuous oral
anticoagulation with either VKA or NOAC [15].
However, the uninterrupted NOAC strategy does not reflect
current clinical practice as most centers still use a minimally
interrupted NOAC strategy [16]. There is limited data demon-
strating the safety and efficacy of aminimally interruptedNOAC
strategy. The aim of the present study was to compare the
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incidence of bleeding and thromboembolic complications of
minimally interrupted NOAC versus uninterrupted VKA in pa-
tients undergoing catheter ablation of AF.
2 Methods
2.1 Study population
We evaluated consecutive patients who underwent catheter
ablation of AF from January 2013 to April 2017 in the
Erasmus Medical Center, Rotterdam, the Netherlands. We in-
cluded patients with 2 specific anticoagulation regimens. The
first group included patients who used periprocedural uninter-
rupted VKA (either acenocoumarol or marcoumar). The strat-
egy of uninterrupted VKAwas introduced in our institution at
the end of 2012. The second group included patients who used
periprocedural minimally interrupted NOAC (1 or 2 doses
withheld). In February 2013, our first patient underwent cath-
eter ablation using a minimally interrupted NOAC strategy.
Patients who did not use oral anticoagulation and were accept-
ed for catheter ablation of AF usually received a NOAC.
2.2 Pre- and periprocedural protocol
All patients received therapeutic oral anticoagulation for at
least 3 weeks prior to ablation. In patients using VKA the
target INR level at the day of the procedure was 2.0 to 2.5.
In patients using NOACs, anticoagulation was withheld for
24 h before the procedure (1 or 2 doses withheld). A cardiac
CT was routinely performed weeks to months prior to abla-
tion. CT imaging was mainly used to assess PV anatomy.
Rarely, a left atrial thrombus could be found as an incidental
finding. A preprocedural transesophageal echocardiogram
was routinely performed on the same day or 1 day prior to
ablation to exclude left atrial appendage (LAA) thrombus. In
the case of LAA thrombus the procedure was canceled or
postponed. During the procedure, a bolus of heparin was ad-
ministered after sheath placement. Furthermore, immediately
after transseptal puncture another bolus of heparin was given
and a continuous heparin pump was started and adjusted to
maintain an ACT of at least 300 s. We did not administer
protamine routinely at the end of the procedure.
2.3 Postprocedural protocol
VKA patients, who had an INR 2.0 or greater at the day of the
procedure, continued their anticoagulation regimen with a tar-
get INR level of 2.0–3.0. VKA patients who had an INR
below 2.0 at the day of the procedure were bridged with in-
travenous UFH for 24 h (starting 2 h after removal of sheaths).
After these 24 h they received low molecular weight heparin
until their INR level was equal or above 2.0. NOAC patients
restarted NOAC in the evening of the procedure. Patients con-
tinued their oral anticoagulation for at least 3 months after the
procedure.
2.4 Study endpoints
Primary bleeding endpoints were major bleeding (within
30 days) as defined by the Bleeding Academic Research
Consortium (BARC) and International Society on
Thrombosis and Haemostasis (ISTH) [17, 18]. The reason to
choose both classifications is that clinical trials reporting ma-
jor bleeding either use ISTH and/or BARC classification. In
our study, BARC types 3 to 5 were considered a major bleed-
ing. Secondary bleeding endpoints were the individual BARC
bleeding types (types 2, 3a, 3b, 3c, 5), clinically relevant non-
major bleeding (CRNMB) according to ISTH [19], and any
clinically relevant bleeding (BARC types 2 to 5; ISTH major
bleeding and CRNMB). BARC type 2 bleeding most closely
aligns with the ISTH CRNMB [19].
The primary thromboembolic endpoint was a composite of
stroke, transient ischemic attack (TIA), or other systemic em-
bolism within 30 days.
2.5 Statistical analysis
Continuous parameters are presented as the mean ± SD as they
were normally distributed. Categorical data are presented as
frequencies and percentages. Comparisons between groups
were performed with an independent Student t test, chi-square
tests, or Fisher exact test. A P-value < 0.05 was considered sta-
tistically significant. Statistical analyses were performed using
SPSS software (SPSS, version 21; IBM, Chicago, Illinois).
3 Results
A total of 637 patients (mean age 60 ± 9 years, 69% male)
were included in the analysis, 520 patients (82%) used unin-
terrupted VKAs and 117 patients (18%) had a minimally
interrupted NOAC strategy. In the NOAC group, the follow-
ing NOACswere used: dabigatran (n = 68), apixaban (n = 30),
rivaroxaban (n = 14), and edoxaban (n = 5). The NOAC group
comprised more patients with long-standing persistent AF and
a lower proportion of patients with a CHA2DS2-VASc ≥ 2
(Table 1). All other baseline variables were similar between
groups. Figure 1 demonstrates the increased use of NOAC
over the years in our AF ablation population.
3.1 Bleeding complications
The rates of major bleeding, either by BARC or ISTH criteria,
were similar between groups (Table 2). The rate of any clini-
cally relevant bleeding (BARC types 2–5; composite of ISTH
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major bleeding and CRNMB) was lower with NOACs com-
pared with VKAs. This difference was mainly due to a differ-
ence in clinically relevant non-major bleeding (CRNMB or
BARC type 2) (Table 2). No patient in either group had a
BARC type 3c (i.e., intracranial bleeding) or type 5 bleeding
(i.e., fatal bleeding). Cardiac tamponade occurred in 4 patients
(0.8%) of the VKA group and in 1 patient (0.9%) of the
NOAC group (P = 1.00).
3.2 Thromboembolic complications
There were no differences in the systemic thromboembolic
event rates between both groups (0.6% versus 0%, P = 1.00)
(Table 2). In the VKA group, 1 patient (0.2%) experienced a
vertebrobasilar stroke 3 days after the procedure. Three
months after the procedure, this patient had a modified
Rankin score of 1. Furthermore, 2 patients (0.4%) in the
VKA group experienced a TIA 1 day after the procedure.
They had an uneventful recovery. No patient in the NOAC
group experienced a systemic thromboembolic event. No
deaths occurred.
4 Discussion
Themain findings of our study are that (1) the rate of clinically
relevant non-major bleeding was lower in patients with a min-
imally interrupted NOAC strategy compared with those with
an uninterrupted VKA strategy, and (2) the rates of major
bleeding and thromboembolic events were similar between
groups.
Uninterrupted use of vitamin K antagonists (VKA) as
periprocedural anticoagulant is currently widely accepted for
patients undergoing catheter ablation of AF who are using
VKA. However, there is an increased use of NOACs in the
current AF ablation population. Despite initial concerns on the
safety of using periprocedural NOAC [20], nowadays, several
large RCTs have demonstrated the safety and efficacy of un-
interrupted use of NOACs (i.e., dabigatran, rivaroxaban,
apixaban) during AF ablation [5, 6, 12] (Table 3).
Table 1 Baseline characteristics
Characteristic Uninterrupted Interrupted P-
valueVKA NOAC
N = 520 N = 117
Age (years), mean ± SD 60 ± 10 60 ± 9 0.55
Male sex, n (%) 354 (68) 84 (72) 0.43
Atrial fibrillation, n (%): 0.048
Paroxysmal 392 (76) 86 (74)
Persistent 116 (22) 24 (20)
Long-standing persistent 10 (2) 7 (6)
Hypertension 217 (42) 44 (38) 0.41
Diabetes mellitus 52 (10) 5 (4) 0.05
Coronary artery disease 62 (12) 7 (6) 0.06
Congestive heart failure 20 (4) 2 (2) 0.25
Left ventricular dysfunction 18 (3) 5 (4) 0.58
LA diameter (mm), mean ± SD 42 ± 6 43 ± 7 0.56
CHA2DS2-VASc score ≥ 2, n (%) 245 (47) 40 (34) 0.02
HAS-BLED score ≥ 3, n (%) 31 (6) 4 (3) 0.30
Body mass index, mean ± SD (kg/m2) 27.7 ± 4.1 27.2 ± 3.3 0.23
Technique of catheter ablation, n (%): 0.09
Cryoballoon 100 (19) 33 (28)
Radiofrequency 402 (78) 83 (71)
Laser 18 (3) 1 (1)
LA = left atrium, NOAC = novel oral anticoagulant, VKA = vitamin K antagonist
Fig. 1 Proportion of periprocedural NOAC and VKA use over the years
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In clinical practice, however, most centers still use a min-
imally interrupted NOAC strategy [16]. The European
Snapshot Survey on Procedural Routines in Atrial
Fibrillation Ablation (ESS-PRAFA) in 2015 demonstrated
that AF ablations were performed with a minimally
interrupted NOAC strategy (1–2 doses withheld) in 53% of
procedures, interrupted NOAC ≥2 days in 34%, and an unin-
terrupted NOAC strategy in 14% [16]. The ABlation
peRIoperative DabiGatran in use Envisioning in Japan
(ABRIDGE-J) randomized trial demonstrated that
anticoagulation with minimally interrupted dabigatran (1 or
2 doses withheld) was associated with fewer ISTH major
bleeding complications than uninterrupted VKA with no in-
crease in thromboembolic events (Table 3) [13]. In addition,
the Apixaban Evaluation of Interrupted Or Uninterrupted
anticoagulation for ablation of atrial fibrillation (AEIOU) ran-
domized trial showed no difference between continuous
apixaban compared with minimally interrupted apixaban (1
dose withheld) with regard to major bleeding (BARC 3–5)
or thromboembolic events (Table 3) [21]. Finally, a recent
meta-analysis of 4 randomized and 9 prospective observation-
al studies (N = 5463) found that minimally interrupted and
continuous NOAC strategy were both safe and non-inferior
strategies compared with uninterrupted VKA [14]. Our study
extends on these results demonstrating less clinically relevant
non-major bleeding events with minimally interrupted NOAC
in comparison with uninterrupted VKA without compromis-
ing thromboembolic safety.
Table 2 Primary and secondary end points
Uninterrupted Interrupted P-
valueVKA NOAC
N = 520 N = 117
Primary bleeding endpoints
BARC 3–5 bleeding, n (%) 22 (4.2) 4 (3.4) 0.70
ISTH major bleeding, n (%) 45 (8.7) 7 (6.0) 0.34
Secondary bleeding endpoints
Bleeding requiring medical attention that does not fit the criteria for types 3–5 (BARC 2), n (%) 43 (8.3) 3 (2.6) 0.03
Bleeding with hemoglobin drop of 30 to < 50 g/L or requiring transfusion (BARC 3a), n (%) 10 (1.9) 3 (2.6) 0.72
Bleeding with hemoglobin drop of ≥ 50 g/L, or requiring surgery or iv vasoactive agents, or
cardiac tamponade (BARC 3b), n (%)
12 (2.3) 1 (0.9) 0.48
BARC 2–5 bleeding, n (%) 65 (12.5) 7 (6.0) 0.04
CRNMB, n (%) 20 (3.8) – 0.03
ISTH major bleeding and CRNMB, n (%) 65 (12.5) 7 (6.0) 0.04
Primary thromboembolic endpoint
Stroke, TIA, or other systemic embolism, n (%) 3 (0.6) – 1.00
BARC=BleedingAcademic Research Consortium, CRNMB= clinically relevant non-major bleeding, ISTH = International Society on Thrombosis and
Haemostasis, NOAC= novel oral anticoagulant, TIA = transient ischemic attack, VKA = vitamin K antagonist
Table 3 Overview of major bleeding and thromboembolic events in large randomized controlled trials comparing periprocedural NOAC and VKA in
patients undergoing catheter ablation of AF
Trial BARC 3–5 bleedings ISTH major bleeding Thrombo-embolic events
RE-CIRCUIT [5] – VKA, N = 318 NA 6.9% 0.3%
RE-CIRCUIT [5] – uninterrupted dabigatran, N = 317 NA 1.6%* 0.0%
VENTURE-AF [6] – VKA, N = 124 NA 0.8% 0.8%
VENTURE-AF [6] – uninterrupted rivaroxaban, N = 124 NA 0.0% 0.0%
AXAFA [12] – VKA, N = 315 4.1% 4.4% 0.0%
AXAFA [12] – uninterrupted apixaban, N = 318 2.5% 3.1% 0.6%
ABRIDGE-J [13] – VKA, N = 222 NA 5.0% 0.5%
ABRIDGE-J [13] – interrupted dabigatran, N = 220 NA 1.4%* 0.0%
AEIOU [21] – uninterrupted apixaban, N = 150 1.3% NA 0.7%
AEIOU [21] – interrupted apixaban, N = 145 2.1% NA 0.7%
*Statistically significant difference in comparison to the VKA group. BARC =Bleeding Academic Research Consortium, ISTH = International Society
on Thrombosis and Haemostasis, NA = not available, NOAC = novel oral anticoagulant, TIA = transient ischemic attack, VKA= vitamin K antagonist
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One of the reasons to choose an uninterrupted NOAC strat-
egy instead of a minimally interrupted NOAC strategy is to
maximally reduce the incidence of thromboembolic events.
However, the risk of a systemic thromboembolic event using
a minimally interrupted NOAC strategy is already low (<
0.7%) [13, 14, 21]. Furthermore, continuous anticoagulation
does not prevent all acute brain lesions, which can be caused
by debris from ablation lesions, air emboli, or small thrombi
[22]. This was demonstrated by the MRI substudy of the
AXAFA trial in which acute brain lesions occurred in 27%
of patients despite uninterrupted apixaban [12]. Further re-
search is required to establish the optimal NOAC dosing strat-
egy (minimally interrupted or uninterrupted) with regard to
both bleeding and thromboembolic risk. Another question is
whether every NOAC is effect ive in prevent ing
periprocedural thromboembolic complications. RCTs with
dabigatran (RE-CIRCUIT) and rivaroxaban (VENTURE-
AF) did not show any thromboembolic events [5, 6], while
RCTs with apixaban (AXAFA, AEIOU) showed a low throm-
boembolic event rate [12, 21].
4.1 Study limitations
There were differences in baseline characteristics between the
study groups. The VKA group had a higher proportion of
patients with a CHA2DS2-VASc ≥ 2 in comparison to the
NOAC group (47% versus 34%). This difference can be ex-
plained by the fact that in patients who did not use an oral
anticoagulant (low CHA2DS2-VASc score) and were accepted
for catheter ablation, a NOAC was preferentially started as
periprocedural anticoagulation regime. This difference in
CHA2DS2-VASc score could potentially lower the risk of
thromboembolic and bleeding events in the NOAC group.
Furthermore, patients used different NOACs in the present
study. The limited number of NOAC patients precluded fur-
ther subanalysis for the different NOACs.
5 Conclusions
In patients undergoing catheter ablation of AF, a minimally
interrupted NOAC strategy was associated with fewer clini-
cally relevant non-major bleeding compared with uninterrupt-
ed VKA. The risk of major bleeding and thromboembolic
events was similar between both strategies. Our study rein-
forces the safety and efficacy of a minimally interrupted
NOAC strategy as periprocedural anticoagulant in patients
undergoing catheter ablation of AF.
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